Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

PVCT Provectus Biopharmaceuticals Inc (QB)

-0.0001 (-0.08%)
Nov 29 2023 - Closed
Delayed by 15 minutes


Draw Mode:

Volume 101,347
Bid Price 0.1176
Ask Price 0.1255
News -
Day High 0.13


52 Week Range


Day Low 0.117
Company Name Stock Ticker Symbol Market Type
Provectus Biopharmaceuticals Inc (QB) PVCT OTCMarkets Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.0001 -0.08% 0.1255 15:40:32
Open Price Low Price High Price Close Price Prev Close
0.1256 0.117 0.13 0.1256
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
22 101,347 $ 0.122573 $ 12,422 - 0.056 - 0.1895
Last Trade Time Type Quantity Stock Price Currency
15:38:37 14,172 $ 0.1255 USD

Provectus Biopharmaceuticals Inc (QB) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
54.54M 419.50M 364.56M 989k -3.56M -0.01 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Provectus Biopharmaceuti... (QB) News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No PVCT Message Board. Create One! See More Posts on PVCT Message Board See More Message Board Posts

Historical PVCT Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.1340.13990.11530.1277026124,067-0.0085-6.34%
1 Month0.0740.17350.07260.1267834453,8060.051569.59%
3 Months0.108250.17350.0560.1029122279,3360.0172515.94%
6 Months0.13170.17350.0560.1082698226,062-0.0062-4.71%
1 Year0.06270.18950.0560.122481263,4670.0628100.16%
3 Years0.06310.18950.00050.0820184269,3160.062498.89%
5 Years0.06550.18950.00050.0736738275,4550.0691.6%

Provectus Biopharmaceuti... (QB) Description

Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases based on a class of synthetic small molecule immuno-catalysts called halogenated xanthenes, led by rose bengal sodium (RBS). Provectus' proprietary, patented, pharmaceutical-grade RBS is the active pharmaceutical ingredient in the investigational drug and preclinical formulations of our drug development programs. Pharmaceutical-grade RBS displays different therapeutic effects at varying concentrations, and can be formulated for delivery by several routes of administration. RBS targets disease in a bifunctional manner. Direct contact may lead to cell death or repair depending on the disease treated and the RBS concentration utilized. Multivariate immune signaling, activation, and response may follow that manifests as stimulatory, inhibitory, or both. Provectus is the first entity to advance an RBS formulation into clinical trials, and the first and only entity to date to consistently make pharmaceutical-grade RBS at a purity of nearly 100%. Our drug pipeline includes clinical programs in oncology, dermatology, and ophthalmology; proof-of-concept in vivo programs in oncology, hematology, wound healing, and animal health; and preclinical in vitro programs in infectious diseases and tissue regeneration. Information about our clinical trials can be found at For information about Provectus, please visit

Your Recent History